{"id":"W4288950951","doi":"10.1016/j.ejca.2022.03.016","title":"EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Chugai Pharmaceutical; Genentech; Geistlich Pharma; PharmaMar; Ono Pharmaceutical; Eisai; NuCana; EMD Serono; Mersana Therapeutics; Deciphera Pharmaceuticals; Clovis Oncology; Incyte; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Quality of life (healthcare); Medicine; Cervical cancer; Internal medicine; Population; Chemotherapy; Oncology; Cancer; Physical therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000511087,0.0002105649,0.000717805,0.0001798361,0.0000841025,0.00000989861,0.0001139412,0.00002538874,0.001082406],"category_scores_gemma":[0.0001404981,0.0001477483,0.0001373932,0.0004873371,0.0001013686,0.00006885237,0.0000696518,0.0004210779,5.974617e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004313008,"about_ca_system_score_gemma":0.0002314373,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001377947,"about_ca_topic_score_gemma":0.00001297983,"domain_scores_codex":[0.9972888,0.0004001654,0.0008620808,0.0002437222,0.0009556587,0.0002495444],"domain_scores_gemma":[0.9977017,0.0002441206,0.001196143,0.0002141914,0.0003238216,0.0003200431],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1773171,0.002218303,0.5110785,0.001007607,0.004992351,0.0003108396,0.004854623,0.0005748723,0.003454392,0.00002952742,0.0004803887,0.2936814],"study_design_scores_gemma":[0.03325811,0.02058142,0.9394757,0.000553622,0.0003775095,0.00001485846,0.0004876168,0.000008502902,0.001881489,0.000008463625,0.003157872,0.0001948601],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993101,0.004049908,0.00001640933,0.00035377,0.000933809,0.0002783219,0.00002063974,0.00001146422,0.001234696],"genre_scores_gemma":[0.9986867,0.0004628145,0.00004029728,0.0004055382,0.0002396688,0.00003339778,0.000002933794,0.00004367486,0.00008501873],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4283971,"threshold_uncertainty_score":0.9998307,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0221888486003094,"score_gpt":0.2960530835257411,"score_spread":0.2738642349254317,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}